The purpose of Renal Cancer: Methods and Protocols is to introduce the surgeon, clinician, investigator, and research scientist to the basic methods employed in the diagnosis and treatment of renal cancer. Treatment of localized renal cancer is surgical. Treatment of metastasis with resection, radiotherapy, chemotherapy, and immunotherapy has had limited results. Therefore, new avenues of treatment are necessary. In planning this work, I have attempted to incorporate coverage by specialists from a variety of disciplines, each applying their individual expertise in renal cancer therapy. Though many of the participating authors are urologists, there are also valuable contributions from medical oncologists, laboratory inv- tigators, and pathologists. One of the inherent problems in publishing a book that describes molecular techniques, especially those techniques that are rapidly evolving, is that some of these may become obsolete after a few years. However, many of the procedures detailed here are standard approaches that have already wi- stood the test of time. Reverse transcriptase PCR, or RT-PCR, a technique that produces m- tiple copies of selected sequences of DNA, has a sensitivity of a millionfold amplication of a single cell, and thus constitutes a very precise technique for measuring the presence of tumor cells. By combining this technique with genomic hybridization, cadherin,ß and metalloproteinase expression we may then reveal other important factors in the detection, staging, aggressiveness, and treatment of this disease.

Includes supplementary material: sn.pub/extras

Klappentext
Because renal cancer can be managed successfully only when localized, there is a great need to develop new treatments for patients with advanced or metastatic disease. In Renal Cancer: Methods and Protocols, Jack H. Mydlo, MD, and a panel of leading clinicians and researchers review every aspect of the latest surgical, medical, and immunological therapies that can be used in the diagnosis and treatment of renal cancer. These broadly experienced investigators also present a practical account of their best basic research methods, including the use of reverse transcriptase PCR combined with genomic hybridization, cadherin, and metalloproteinase expression to reveal important factors in the detection, staging, aggressiveness, and treatment of this disease. Gene therapy, the generation of monoclonal antibodies, and the use of interferon alpha, GM-CSF, and IL-6 are also discussed. In vivo assays are provided for analyzing angiogenesis, anti-angiogenesis, and general renal tumor biology as a prelude to human clinical trials.
Comprehensive and pioneering, Renal Cancer: Methods and Protocols offers urologists, medical oncologists, laboratory investigators, and pathologists a practical collection of the major cutting-edge techniques and therapies for renal cancer today, together with a view of the highly promising future of gene therapy.

Inhalt
Renal Cell Carcinoma.- Pathology of Kidney Tumors.- In Vitro Experimental Techniques.- Telomerase Assay in Renal Cancer.- Comparative Genomic Hybridization.- Analyzing the FHIT Gene by RT-PCR, Western Blotting, and Immunohistochemistry.- Detection of Apoptosis in Renal Cell Carcinoma.- Fluorescence In Situ Hybridization (FISH) to Metaphase and Interphase Chromosomes.- Polymerase Chain Reaction Detection of DNA Sequence Deletions.- Matrix Metalloproteinases and Their Inhibitors.- Purification of Growth Factor mRNA in Renal Tissues:bFGF-2, FGF-2, TGF?, and EGFR.- Laser-Capture Microdissection.- Expression of c-met and WT-1.- Molecular Analysis of the von Hippel-Lindau Disease Gene.- Experimental Models and Methods in Antibody Targeting of Renal Cell Carcinoma.- In Vivo Experimental Techniques.- Orthotopic Model of Renal Cell Carcinoma.- Murine Animal Model.- Angiogenesis Assays.- Antiangiogenic Approaches to Renal Cell Carcinoma.- Clinical Trials and Experiments.- Interferon Alpha, GM-CSF-Activated T Cells, and IL-6 in Renal Cell Carcinoma.- Immunotherapeutic Approach to Cancer with Cutaneous DNA Vaccination.- Monoclonal Antibodies.- Treatment Strategies in Metastatic Renal Cell Carcinoma.- 23 Assessment of T-Cell Immune Dysfunction in Patients with Renal Cell Carcinoma.- Transforming Growth Factor-?1 as a Novel Marker of Response to Therapy for Renal Cell Carcinoma.- Static and Flow Cytometry.